UBS’s Cardiff Oncology CRDF Stock Holding History

UBS’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-12	Closed	-$3K	–	10401
2014 Q2	$3K	Buy	+12	New	+$3.84K	﹤0.01%	9807
2014 Q1	–	Sell	-52	Closed	-$21K	–	10474
2013 Q4	$21K	Buy	+52	New	+$23.1K	﹤0.01%	8081

Other funds holding CRDF

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

UBS's CRDF Position: Q3 2014 in Review

UBS sold out of Cardiff Oncology (CRDF) in Q3 2014, closing a stake of 12 shares — an estimated $3K sold.

UBS first reported a position in CRDF in Q4 2013 and held it in 2 quarters. The position peaked at $21K in Q4 2013. 22 funds tracked by Wall St. Rank hold CRDF as of Q3 2014.

UBS reported no remaining Cardiff Oncology position as of Q3 2014 after selling out during the quarter.
UBS sold 12 Cardiff Oncology shares in Q3 2014, an estimated $3K.
UBS first reported a position in Cardiff Oncology in Q4 2013 and held it in 2 quarters.
UBS's Cardiff Oncology position peaked at $21K in Q4 2013.
22 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.